but no other known tyrosine kinases. Imatinib also inhibits the abl protein of non-cancer cells but cells normally have additional redundant tyrosine kinases which allow them to continue to function even if abl tyrosine kinase is inhibited. Some tumor cells, however...
Imatinib is a tyrosine kinase inhibitor widely used in the treatment of chronic myelogenous leukemia. Originally designed to target the chronic-myelogenous-leukemia-specific tyrosine kinase bcr-abl, imatinib has since been shown to inhibit a number of important tyrosine kinases involved in cell growth ...
The mechanism of action is not known, but one possible target for the action of imatinib is inhibition of the KIT receptor on mast cells.doi:10.1080/... KK Eklund,H Joensuu - 《Annals of Medicine》 被引量: 282发表: 2009年 Dynamic modeling of imatinib-treated chronic myeloid leukemia: func...
Kit positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST) Adult adjuvant treatment following resection of Kit positive GIST Mechanism of Action Imatinib mesylate is a protein tyrosine kinase inhibitor that inhibits bcr-abl tyrosine kinase, a constitutively abnormal tyrosine...
Imatinib Imatinib may decrease the excretion rate of Ivermectin which could result in a higher serum level. Indinavir The metabolism of Ivermectin can be decreased when combined with Indinavir. Infliximab The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Inflixima...
Also, dasatinib has in vitro activity against leukemic cell lines that are either sensitive or resistant to imatinib. It has been suggested that dasatinib can overcome imatinib resistance caused by BCR-ABL kinase domain mutations because it does not require interaction with some of the residues ...
Imatinib The metabolism of Montelukast can be decreased when combined with Imatinib. Indinavir The metabolism of Montelukast can be decreased when combined with Indinavir. Indomethacin The metabolism of Montelukast can be decreased when combined with Indomethacin. Infliximab The metabolism of Montelukast can...
We report that imatinib, an Abl tyrosine kinase inhibitor, robustly decreases SARS-CoV-2 infection and uncover a mechanism of action. We show that imatinib inhibits the infection of SARS-CoV-2 and its surrogate lentivector pseudotype. In latter, imatinib inhibited both routes of viral entry, ...
As the crosstalk between these two entities is tightly controlled by the release of polypeptide mediators activating signalling pathways through several receptor tyrosine kinases (RTKs), RTK inhibitors have been designed. These inhibitors have shown exciting clinical impacts, such as imatinib mesylate, ...
Fig 3. Induction of oxidative DNA damage in human peripheral blood cells (HPBCs), after exposure to imatinib mesylate (IM) at different concentrations (0, 0.001, 0.01, 0.1, 1 and 10 mg/mL) for 4 (A) and 24 (B) h evaluated by the Fpg-modified comet assay. The % of tail DNA ...